Education
About Us
Working with TipRanks
Follow Us
Innoviva (INVA)
:INVA
INVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.67 - $22.00
Previous CloseN/A
Volume64.08K
Average Volume (3M)744.69K
Market Cap
$1.10B
Enterprise Value$1.72B
Total Cash (Recent Filing)$497.73M
Total Debt (Recent Filing)$450.90M
Price to Earnings (P/E)51.8
Beta0.35
Next Earnings
Oct 29, 2025EPS Estimate
0.46Last Dividend Ex-Date
Sep 08, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.77
Shares Outstanding63,021,015
10 Day Avg. Volume705,121
30 Day Avg. Volume744,693
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)1.57
Price to Sales (P/S)3.03
P/FCF Ratio5.78
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit5.25
Enterprise Value/Ebitda15.39
Forecast
1Y Price Target
$35.60Price Target Upside106.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
EarningsThe company reported net earnings of $0.77 per diluted share, handily beating the forecast for net earnings of only $0.57 per diluted share.
Financial PerformanceInnoviva's financial results demonstrate strong underlying operational performance, with multiple revenue streams exceeding expectations.
Product DevelopmentAn 85% probability of approval is assigned to zoliflodacin based on favorable clinical data, drawing attention to a potential near-term regulatory decision.
Bears Say
Market ChallengesThe underlying products for the GSK royalties face LOE and IRA pressures, shifting the focus to the IST business to drive growth in a challenging commercial environment.
Patent CliffThe company's 2031 royalty-related patent cliff is anticipated to start weighing on stock performance, reflecting historical trends in the pharma sector.
Innoviva News
INVA FAQ
What was Innoviva’s price range in the past 12 months?
Innoviva lowest stock price was $16.67 and its highest was $22.00 in the past 12 months.
What is Innoviva’s market cap?
Innoviva’s market cap is $1.10B.
When is Innoviva’s upcoming earnings report date?
Innoviva’s upcoming earnings report date is Oct 29, 2025 which is in 20 days.
How were Innoviva’s earnings last quarter?
Innoviva released its earnings results on Aug 06, 2025. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.499 by $0.271.
Is Innoviva overvalued?
According to Wall Street analysts Innoviva’s price is currently Undervalued.
Does Innoviva pay dividends?
Innoviva pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva dividends here
What is Innoviva’s EPS estimate?
Innoviva’s EPS estimate is 0.46.
How many shares outstanding does Innoviva have?
Innoviva has 63,021,015 shares outstanding.
What happened to Innoviva’s price movement after its last earnings report?
Innoviva reported an EPS of $0.77 in its last earnings report, beating expectations of $0.499. Following the earnings report the stock price went up 1.151%.
Which hedge fund is a major shareholder of Innoviva?
Currently, no hedge funds are holding shares in INVA
Innoviva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.60 (106.98% Upside)
$35.60 (106.98% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 40.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.86%
12-Months-Change
Fundamentals
Return on Equity
5.60%
Trailing 12-Months
Asset Growth
8.87%
Trailing 12-Months
Company Description
Innoviva
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Stock 12 Month Forecast
Average Price Target
$35.60
▲(106.98% Upside)
Technical Analysis
Xeris Pharmaceuticals
―
CureVac
―
Tourmaline Bio
―
LENZ Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
9.89% Insiders
27.93% Mutual Funds
14.44% Other Institutional Investors
15.86% Public Companies and
Individual Investors